Lacosamide is a new antiepileptic drug (AED) marketed as Vimpat with three different
formulations, tablets, oral syrup and a solution for intravenous infusion. Lacosamide is
approved as adjunctive therapy in epilepsy patients with partial onset seizures with or
without secondary generalization. The i.v. solution is used in patients in which oral
administration is not possible or adequate. Bioequivalence with oral tablets and safety could
be demonstrated in healthy volunteers and in patients switched from tablets to Lacosamide
i.v. solution. A recently published study demonstrates the feasibility of single loading
doses up to 300 mg. The aim of this Lacosamide i.v. registry is to collect systematically
data on the safety, tolerability and administration procedures when Lacosmide i.v. is used in
routine daily clinical practice, mainly in hospitals. These data will help treating
physicians to optimize the use of Lacosamide i.v. in clinical routine.
Details
Lead Sponsor:
University Hospital Schleswig-Holstein University of Schleswig-Holstein